TMCnet News

Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Drug Forecast and Market Analysis to 2024 - Research and Markets
[July 25, 2016]

Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Drug Forecast and Market Analysis to 2024 - Research and Markets


Research and Markets has announced the addition of the "Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024" report to their offering.

Argentina ranks fourth among pharmaceutical markets in Latin America. This growth will be primarily driven by overall pharmaceutical market growth and increasing use of recombinant prophylactic therapies by hemophilia patients. According to our primary research, the majority of Argentine hemophilia patients have access to factor replacement products through private insurance plans or through the national social security program. However, the national insurance program only covers on-deand treatment and plasma-derived concentrates.



Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.


- Detailed information on the key drugs in Argentina including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Argentina from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting Argentina Hemophilia A and B market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Unmet Need and Opportunity

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/jrw6df/hemophilia_a_and


[ Back To TMCnet.com's Homepage ]